logo

Optibiotix Health - Rapidly Transitioning to Commercial Phase

Writen by Riccardo Lowi

Rapidly Transitioning to Commercial Phase

KEY INVESTOR MESSAGES

  • Preventing and treating diseases through the modulation of the microbiome is one of the most exciting frontiers of healthcare, and a fast growing market
  • OptiBiotix Health PLC (LON:OPTI), an innovative life sciences company focused on human microbiome, is rapidly transitioning from product development to the commercial stage with early revenues and commercial deals with major corporates including Tata and DSM
  • Underpinned by a strong scientific rationale and clinical studies, OptiBiotix Health PLC (LON:OPTI) products help managing significant health problems as weight loss, high cholesterol and hypertension
  • OptiBiotix Health PLC (LON:OPTI) commercial push is currently directed towards the rapidly growing consumer health market
  • A rich deal pipeline is likely to translate in material revenue growth (£1mln+) within 12 months

 

OVERVIEW

OptiBiotix focuses on managing and treating widespread medical conditions, such as obesity and high cholesterol, through the modulation of the human microbiome. This has the potential to be a substantial opportunity in an emerging market fashioned by new research into the human microbiome which has created a unique window of opportunity for compounds which can modify the human microbiome and bring specific health benefits. US researchers and clinicians presenting at the 2016 Medical Innovation Summit identified the microbiome as the world’s top innovation, describing it as healthcare’s ‘most promising and lucrative frontier’.

To exploit the diversity of opportunities, OptiBiotix’s has developed a number of technology platforms using different approaches to modulate the microbiome. These technology platforms have moved through the development process of laboratory studies, independent human studies with world-renowned key opinion leaders, and manufacturing scale up.  This has substantially reduced technical and clinical risk.

By way of introduction, microbiome refers to the trillions of bacteria colonizing our skin and gut; in normal "physiological" conditions our body has 10x more bacterial cells than own cells.

A rapidly growing body of scientific literature shows that specific health benefits can be achieved by actively intervening on the composition and activity of our microbiome. As an example, by intervening on the bacteria populating our gut, we can influence how foods are digested, absorbed or directly excreted, thereby controlling the quality and the size of our calorific intake.

To that end, OptiBiotix has developed several products across four technology platforms, addressing large medical problems as weight loss, high cholesterol and high blood pressure.

One platform, SkinBiotix, was successfully spun-out in April 2017 and listed on the London stock exchange as SkinBiotherapeutics. It has now a market capitalization of about £12mln; OptiBiotix still owns approximately 42% of its capital.

The main features of OptiBiotix key products are summarized in Table 1.

OptiBiotix is pursuing a commercial strategy based on deal opportunities across multiple levels of the value chain, starting from manufacturing agreements such as the profit sharing agreement signed in May 2017 with Sacco Srl for the production of LPLDL and Knighton Foods (November 2017), which is a 100% owned subsidiary of Premiere Foods.

The Company is also seeking deals for the supply of white label and branded products to food producers and consumer health companies, up to distribution agreements directly with retailers. (new slide below which also includes SlimBiome)

This multi-channel strategy will enable OptiBiotix to maximize the income potential of every product, whilst limiting the risk related to any individual deal.

ADDRESSABLE MARKET

It is hard to precisely estimate the size of the market addressable by OptiBiotix products, as the science behind the therapeutic benefits deriving from the modulation of the human microbiome is still young and new potential applications are continuously discovered. According to Research and Markets, a research firm, the microbiome market is rapidly growing at an annual rate around 23%. 

Furthermore, OptiBiotix products, such as LPLDL, can be combined with existing probiotics to deliver enhanced health benefits. Markets and Markets, a business intelligence firm, expects the global probiotic market to growth at a 7% annual rate from c. $42bn in 2016 to c. $64bn in 2022. Within that, the supplement segment alone is expected to grow in the US from $2bn to about $3.3bn by 2021.

Although the modulation of the microbiome is attracting the interest of many companies and investors, OptiBiotix appears to be quite unique in its focus on solving specific health problems, rather than general wellbeing, whilst targeting the consumer health segment, at least in these early days of its commercial expansion.

DEAL FLOW AND FINANCIALS

OptiBiotix is rapidly transitioning from being focused on product development to the market launch of their products.

We understand that the Company is actively pursuing a wide range of commercial deals, including licensing, profit sharing and distribution agreements, across multiple

geographies. In the last couple of years, OptiBiotix has already entered into development and commercial deals with several international companies, including KSF (Slimfast), Tata (x2), DSM and Sacco.

We are confident that the current rich deal pipeline will trigger a significant revenue uptake in the coming quarters. Based on our understanding, a typical commercial deal could generate annual revenue in the £250,000 - £500,000 range; we also note that larger deals in the multi-million range are within the Company's current reach.

We expect the income generated by the ongoing commercial expansion to provide the resources needed to accelerate OptiBiotix commercial push, including the potential acquisition on new IP and products.

From a financial perspective, OptiBiotix, with approx. £1.9mln of cash at the end of May 2017 and an estimated cash burn of c. £90k/month, is self-funded well into 2018, excluding any potential income from new deals.

 

 

Important – Please read this information: This report has been commissioned by OptiBiotix Health plc and prepared and issued by Capital Network for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however, we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Capital Network at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. Capital Network does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Capital Network’s solicitation to effect, or attempt to effect, any transaction in a security. This document is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Capital Network has a restrictive policy relating to personal dealing. Capital Network does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Capital Network may have a position in any or related securities mentioned in this report. Capital Network or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Capital Network within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Capital Network, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication.

OptiBiotix Health plc Timeline

Latest Research

Safety Pays

In pence-per-share terms, the NAV increased by 0.8p during the quarter. This...